Earnings Labs

Imunon, Inc. (IMNN)

Q2 2023 Earnings Call· Sun, Aug 13, 2023

$2.73

-2.50%

Key Takeaways · AI generated
AI summary not yet generated for this transcript. Generation in progress for older transcripts; check back soon, or browse the full transcript below.
Transcript

Operator

Operator

Good morning. My name is Alan, and I will be your operator today. At this time I would like to welcome you to Imunon's Second Quarter 2023 Financial Results Conference Call. [Operator Instructions]. I would like now to turn the call over to Kim Golodetz. Please go ahead.

Kim Golodetz

Analyst

Thank you and good morning everyone. This is Kim Golodetz with LHA. Welcome to Imunon's 2023 second quarter financial results and business update conference call. During today's call, management will be making forward-looking statements regarding Imunon's expectations and projections about future events. In general, forward-looking statements can be identified by words such as expect, anticipates, believes or other similar expressions. These statements are based on current expectations and are subject to a number of risks and uncertainties, including those set forth in the company's periodic filings with the Securities and Exchange Commission. No forward-looking statements can be guaranteed, and actual results may differ materially from such statements. I also caution that the content of this conference call is accurate only as of the date of the live broadcast, August 10, 2023. Imunon undertakes no obligation to revise or update comments made during this call except as required by law. With that said, I would like to turn the call over to Dr. Corinne Le Goff, Imunon's President and Chief Executive Officer. Corinne.

Corinne Le Goff

Analyst

Thank you, Kim. And good morning, everyone. Today, joining me is Jeffrey Church, our Chief Financial Officer. In addition, Dr. Khursheed Anwer, our Chief Science Officer will be available during the Q&A session at the end of our prepared remarks. As I have discussed during previous calls, Imunon's growth and development is dependent on four pillars. The one I'd like to spend most of our time on today is the development of our PlaCCine prophylactic vaccines modality as an out licensing and partnership opportunity. PlaCCine is our proprietary mono-or multi-cistronic non-viral and synthetic DNA technology for the expression of pathogen antigens. It is currently being evaluated in preclinical studies for the development of next-generation vaccines. We have made exceptional progress advancing this technology as a Prophylactic Vaccines modality with important features, both as a commercial product platform and as a potential solution to addressing the next pathogens of interest. I will review some of our most recent preclinical data with PlaCCine, which suggests this asset has been derisked and is performing as we anticipated. During the quarter, Dr. Anwer presented results from preclinical studies in a PlaCCine COVID-19 vaccine at the Vaccine Technology Summit Conference and 2023 Virus and Cells Gordon Research Conference in Barcelona that demonstrated characteristics that address the limitations of current commercial vaccines by offering enhanced breadth of protection to emerging variants, persistence and robust cellular immunity, as well as stability at workable temperatures. Importantly, humoral immune responses specific to the SARS-CoV-2 spike antigen were persistent over a 14-month post-vaccination period, while the T-cell responses from PlaCCine COVID-19 vaccines after 14 months were higher than a commercial mRNA vaccine. In another mouse study, the humoral response to a single dose of a commercial mRNA vaccine plateaued within 14 days after vaccination while the response continued to increase…

Jeffrey Church

Analyst

Thank you, Corinne. Details of Imunon's second quarter 2023 financial results are included in the press release we issued this morning and in our Form 10-Q, which we filed today before the market opened. Imunon ended the second quarter with $24.1 million in cash, investments and accrued interest receivable. Our cash or net cash usage for operating activities was $6.8 million in the second quarter of 2023, up from $5.4 million from the prior year period. The increase was primarily due to the cash settlement in April 2023, along with related legal costs for arbitration with a former contract manufacturer for ThermoDox. Cash used by financing activities of $6.2 million during the second quarter of 2023 resulted from the early repayment of the company's loan facility with Silicon Valley Bank. This was offset by equity sales under at-the-market equity facility. Combined with the $1.8 million in planned future sales of Imunon State of New Jersey net operating losses, we believe we have sufficient capital resources to fund the company's operation through 2024. Let me now turn to a review of our financial results. Imunon reported a net loss for the second quarter of 2023 of $5.6 million or $0.61 per share. This compares with a net loss of $6 million or $0.87 per share in the second quarter of 2022. Operating expenses were $5.5 million in the second quarter of 2023. It was down about 10% from the 6.1% that we reported in the second quarter of 2022. Let me break down each one of these line items. Research and development expenses were $3.1 million in the second quarter of 2023, a decrease of about $100,000 from the prior year second quarter. More specifically, research and development costs associated with our PLACCINE DNA vaccine modality increased to $1.3 million from…

Corinne Le Goff

Analyst

Thank you, Jeff. Imunon is tightly focused on harnessing the power of being a system by developing novel DNA-based approaches in immuno-oncology and infectious diseases. We believe that the non-viral DNA will be a key driver of the future of global medicines. We are very excited about the potential at Imunon, to improve the health of millions if not billions of people, while creating significant value for our shareholders. Along our achievements, we have de-risk PLACCINE Modality across several pathogens of interest by demonstrating the immunogenicity and safety of our vaccines. We have generated compelling data in SARS-CoV-2 and IMNN-101, the next-generation COVID-19 signal booster will be in the clinic in Q1 next year. We also have generated excellent immunological response for vaccines against pathogen of concerns, especially Monkeypox, arenaviruses, [inaudible]. We unveiled a state-of-the-art manufacturing site in Hansfield to reduce our compliance on others. We entered into collaborations designed to advance our technology, and we are actively building capabilities for the development of cancer vaccine. Looking forward, we expect to reach several value-creating milestones over the next six to 18 months. Some of them are recording additional interim data on IMNN-001 for vision study and the combination study with bevacizumab in advanced ovarian cancer, and reporting top line data from the OVATION 2 study, starting also the IND for our SARS-CoV-2 vaccine and announcing proof-of-concept vaccine data as well for another virus program. We are very excited to tell you about our programs in more detail in an R&D Day that we plan to hold this fall. We will have several leaders discussing our work during this vital program. So please keep an eye out for more details in the coming weeks. With that, I open up the call to your questions. Operator.

Operator

Operator

We will now begin the question-and-answer session [Operator Instructions] Our first question comes from Emily Bodnar of HC Wainwright.

Emily Bodnar

Analyst

Hi, thanks for taking the question. I guess two on the COVID program. First, can you touch on the remaining steps and studies that you might need before you could submit the IND in the first quarter? And then, do you plan to have the Phase I/II study just be in general healthy volunteers or do you think you might focus development on either like elderly or immunocompromised patients? And then just clarifying time lines for OVATION 2. I think you previously talked about interim data in the third quarter. Is that still happening? And then is top line data supposed to be still on track for the first half of next year? Thank you.

Corinne Le Goff

Analyst

Thank you, Emily. I'll start with the time lines on Ovation. Yes, so I confirm that we should have additional interim data in the third quarter. And for the top lines, we are still planning on having the top lines at the end of this second quarter 2024. To your question on COVID. So I'll ask Dr. Khursheed Anwer to complete my answers. Yes, so we'll be ready to submit our IND in the first quarter. What we are working on at the moment is the production of the clinical vector. We – so we have pretty much set and very much on track for the submission of IND. And when it comes to the Phase I/II trial design, we'll be looking at generally healthy volunteers. I think your question on looking at immunocompromised patients actually is an interesting one or model patients. That's something that we actually will address with our advisers. That could be a subsequent study. Khursheed, do you want to add to what I just said?

Khursheed Anwer

Analyst

Yes, sure. I think you've covered it well. Emily, at least two sets of studies that are IND-enabling are currently in progress. One is to look at the safety of in animals. So that safety study is kind of due to start soon and bio-distribution study, the plans made, and the delivery system goes and how long it takes to clear. So those are the two fundamental IND-enabling studies that will complete the submission of the IND. And as Corinne said, Phase I study will be healthy volunteer, because clearly for Phase II part, we could look into some stratification. As Corinne said, maybe some elderly with morbidity, but discussion with our [audio gap].

Emily Bodnar

Analyst

Okay, great. That’s very helpful. Thank you.

Operator

Operator

Our next question comes from David Bautz from Zacks. Go ahead.

David Bautz

Analyst

Hey, good morning everyone. Thanks for taking the questions. First ones on the PlaCCine technology. Do we have any idea right now about how long the antigen is going to be expressed in someone who gets immunized with PlaCCine? Are we talking days or weeks or months? Do you have any clue right now?

Corinne Le Goff

Analyst

Hi David. Yes, we certainly do. Khursheed, can you please answer the question?

Khursheed Anwer

Analyst

Yes. Yes, of course. Well David, compared to mRNA or put the DNA pays for longer period time, especially in [inaudible]. So with other genes, such as reporter gene, we have seen expression for several weeks. So I anticipate the question of the [inaudible] last several weeks after a single injection or even months.

David Bautz

Analyst

Is there any concern about tolerance development or even an allergic reaction with such long expression of the antigen?

Khursheed Anwer

Analyst

The levels of the antigen are not high or super max to be able to cause any intolerance issue. That generally happens if you have an antigen of protein bolus given over time, supraphysiological levels, then you see intolerance. So these are levels that are enough to initiate immune responses. I don't anticipate intolerance, but again, we haven't specifically looked for that.

Corinne Le Goff

Analyst

What I’d like to add as well, David, is we believe that the increased expression of the antigen or longer expression of the antigen is in fact a benefit, because it gives time to your immune system to build memory cells, right, and that's maybe the concern, a little bit with the RNA but you know memory cells are not too much present.

David Bautz

Analyst

Okay, that sounds good. And then as far as the Phase I study goes, I guess how do you determine what variant you're going to target for that? And then can you change which variant you target, between going from say the Phase I to the Phase II?

Corinne Le Goff

Analyst

That's a good question. So, you know I mentioned that the FDA every year will tell manufacturers which variant to go after. So they are going to use the same principle as they do for the flu vaccines, right. So they met the VPAC make in 2015 that said what the manufacturers need to put into production is Omicron XBB 1.5, which is what we did. The FDA agreed that that was the right thing for us, and then we'll do a Phase I/II, which means that as soon as we start the Phase I, when we get the safe dose from the Phase I, we'll go immediately into Phase II program with the same variants.

David Bautz

Analyst

Okay. So is this system being set up kind of like the flu vaccine, where you're not going to have to basically do animal studies again every year with a different variant. You're just going to be able to plug it in and whichever variant – okay.

Corinne Le Goff

Analyst

And that's what I just mentioned. That's why we're so pleased that the FDA confirmed what we call our plug-and-play strategy, but then you don't have to redo your TUC [ph] studies in animals when you change the cases.

David Bautz

Analyst

Okay, great. Thanks for taking the questions.

Operator

Operator

The next question comes from Kemp Dolliver from Brooklyn Capital Markets.

Kemp Dolliver

Analyst

Great, thank you. Just to continue on with the vaccine discussion. So do you expect you would have Phase I data in the second half of '24, given the timing of the IND filing?

Corinne Le Goff

Analyst

I believe so. That's what we're planning to do again.

Kemp Dolliver

Analyst

Okay. All right, thank you. And then you had originally hoped to file the IND by the end of the year. We're not talking about a significant change in the timeline. But I'm curious, does the change in the timeline reflect the timing of FDA feedback or reflect the pre-IND functions that – or the IND enabling functions that you're doing now?

Corinne Le Goff

Analyst

Right, thank you. Yes, we thought we could be a bit faster with our IND filing, you're correct. I think the shift in the timelines reflect the fact that we wanted to here – to make sure that we would pursue a variant that is the one recommended by the FDA. So we wanted to wait for the June 16 meeting. And then of course, the feedback on our Pre-IND package was a bit delayed compared to what we had thought as well, so that's the reason.

Kemp Dolliver

Analyst

Great. Thank you very much.

Operator

Operator

[Operator Instructions] Our next question comes from James Molloy of Alliance Global Partners. Please go ahead.

James Molloy

Analyst

Hi, good morning. Thank you for taking my questions. Most of them have been answered, but I had a question on the combo with AVASTIN, Phase I/II underway. What's the expectation for the potential interim look for that and moving into a Phase II portion of that trial?

Corinne Le Goff

Analyst

Right, good morning James. So as I mentioned, this trial is under the sponsorship of the Break Through Cancer Foundation. We're supposed to have four centers enrolling patients in this clinical trial. The first center in Anderson is up and running. They have not enrolled any patients yet, but they are definitely up and running. And we are expecting the other centers to join the study in Q3 – I mean maybe September, October time frame this year. For Phase I/II, which means that the first phase of this trial is really to evaluate the dose that we need to administer to patients in combination with AVASTIN and then the Phase II will come after. So it’s a bit difficult at the moment to give you exactly when we can get some first data, but certainly, in the course of 2024, we have more certainty as the new the new centers involve. Khursheed, do you want to add anything to what I said? I know you've been talking with the investors here as well.

Khursheed Anwer

Analyst

Sure. No, you're right. I mean the infill part as Corinne said, is to demonstrate safety in combination with the AVASTIN and the chemo. And once the four sites that we have targeted come on board, the Phase I portion should not take much. I don't want to put a date or time, but I think it's just starting now. So Phase I sources should not take a longer time before we get into Phase II. So September, October – October time we anticipate all sites to be onboard. It's only a matter of, perhaps I would say, three to four months after that.

James Molloy

Analyst

Okay, great, thank you. And is there a – I have on sort of my model expectations for maybe another combo at some point with OPDIVO. Is that something that you guys are still looking at for Epithelial Ovarian Cancer?

Corinne Le Goff

Analyst

Hi James. Yes, so I think I would say, in theory I believe that there is a lot of value in testing IL-12 accommodation, because mechanistically that makes a lot of sense to add an IL-12 with a checkpoint inhibitor for instance, right, because it's all about motivating the macro environment. So we might think about this. I mean, we do one thing at a time right. The reason why we engaged in a combination trial with AVASTIN now is because we have very compelling synergistic data in a preclinical model in mice. But it's not out of the question to think that a combination with a checkpoint inhibitor could be an interesting trial as well.

James Molloy

Analyst

Absolutely. So I know you have limited resources as everyone does. Actually at that point has there been any discussion to the effect of any larger pharma partners that are coming in to partner to help with the R&D?

Corinne Le Goff

Analyst

On the IL-12 program, you’re asking specifically?

James Molloy

Analyst

Really IL-12 or really across the board, looking at the technology stand, that's pretty good. We want to get in on that?

Corinne Le Goff

Analyst

So yes, I mean collaboration and partnership will be key to our operating model. So we'll – certainly we'll seek partnerships. That's why we're also eager to get into a Phase I program with our vaccine modality, so that we can get to this proof of principle in humans, and then I'm sure that that will open doors for collaborations after that.

James Molloy

Analyst

Absolutely. Thank you for taking the questions.

Corinne Le Goff

Analyst

Thank you.

Operator

Operator

This concludes our question-and-answer session. I would like now to turn the conference back over to Dr. Corinne Le Goff for any closing remarks.

Corinne Le Goff

Analyst

Thank you very much. So as you know, we have been using the phrase ‘banking of the future’ to describe our work, and this is exactly what our vision is, is to be the provider of safe and effective vaccines that are superior to current vaccines in terms of durability and buffer protection, that are stable at workable temperatures, that can be manufactured rapidly to respond to evolving pathogens, and offer better compliance for maximization, with no need for a device or virus. We also believe our technology owns excellent promise in immuno-oncology. So we look forward to keeping you informed of our progress for joining us, and we look forward to speaking with you again at our upcoming R&D Day event. Have a very nice day.

Operator

Operator

The conference has now concluded. Thank you for attending today's presentation. You may now disconnect.